At the Computational Cancer Genomics Group, we want to understand the genomic changes that fuel tumor evolution. Traditionally, the understanding of cancer development has been shaped by studying point mutations and their effect on individual genes. However, more sophisticated sequencing technologies, particularly whole-genome and long-read sequencing, have enabled a more comprehensive view of the genomic alterations that riddle cancer cells. These advancements have revealed that structural variation and complex genome rearrangements significantly contribute to genomic instability, tumour heterogeneity and cancer development.

At the Computational Cancer Genomics Group, we want to decipher the mutational processes underlying the variation in the structure of chromosomes, the consequences of these aberrations, and the relationship between genomic complexity and cancer aggressiveness. We are also interested in exploring the dynamic interplay between the cancer genome, the tumour microenvironment, and the immune system. To this end, we leverage whole-genome sequencing data from large international sequencing cohorts and generate multi-omic data from pancreatic cancer tumours and pre-clinical models to obtain a holistic, comprehensive view of the cancer genome. We enjoy working closely with internal and international collaborators, including cancer biologists and clinical teams.

Our ultimate goal is to translate these discoveries into real-world solutions. We aim to develop and apply novel multi-modal genomic biomarkers and therapeutic targets to support early detection and precise stratification of patients, with a focus on pancreatic cancer. We are committed to democratizing access to whole-genome sequencing and other advanced genomic tests, paving the way for a future where personalized precision medicine is a reality for every cancer patient.